_256_384.jpg)
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
If cleared, Merck's drug would be the first pill shown to treat Covid-19, a potentially major advance in efforts to fight the pandemic
Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
It is a recombinant nanoparticle protein-based vaccine
These modules will act as a guide to doctors and health care workers to deal with post-Covid-19 issues
Subscribe To Our Newsletter & Stay Updated
